eTheRNA immunotherapies, the VUB spin-off that recently secured a  EUR 24 million investment to continue the development of mRNA-based immunotherapies, has strengthened its management team with the appointment of Dr. Karl-Josef “Kajo” Kallen as Chief Medical Officer, effective May 1 2016.

Dr. Kallen had several positions related to the development of immunology related therapies in academia and industry. He served as Chief Medical Officer (CMO) and Chief Scientific Officer (CSO) at CureVac, a German biopharmaceutical company that  focusses on the development of mRNA-based medicines, with investigative products for the treatment of prostate cancer that are currently in phase II-studies and several other compounds in earlier development stages. Dr. Kallen was instrumental in establishing key corporate agreements, e.g. the research agreement with Sanofi and DARPA (Defense Advanced Research Projects Agency), the deal with Boehringer Ingelheim, and he also contributed to the instigation for the agreement with the Bill & Melinda Gates Foundations for the development of therapies against infectious diseases. 
 

The full text is available in annex and on http://www.etherna.be/newsroom/news/105-etherna-strengthens-management-team-with-appointment-of-dr-karl-josef-kallen-as-chief-medical-officer